Market Currents
Salix Pharmaceuticals (SLXP) and Progenics (PGNX) report "positive" highly statistically...
-
Tuesday, December 20, 2011, 8:45 AM ETSalix Pharmaceuticals (SLXP) and Progenics (PGNX) report "positive" highly statistically significant results of the Phase 3 of oral methylnaltrexone for the treatment of opioid-induced constipation in subjects with chronic, non-cancer pain. SLXP +11%, PGNX +18.8% premarket. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
